본문바로가기
Q
U
I
C
K

SK bioscience

SK bioscience is growing as a global vaccine developer through continuous investments to R&D and manufacturing infrastructure.

History

2018 - 2024
Into the global healthcare market
  • 2024
  • Obtained WHO PQ for SKYTyphoid, Typhoid Conjugate Vaccine
  • Received A Grade in MSCI ESG Rating 2023
  • 2023
  • Initiate Submission of Phase III Study Investigational New Drug Amendment to the U.S. FDA of 21-Valent Pneumococcal Conjugate Vaccine Candidate (Sanofi)
  • Development licensing agreement with Hilleman Laboratories for joint development of a second-generation Zaire Ebola virus vaccine.
  • Implements a Laboratory Information Management System(LIMS)
  • Signed MOU with Serbia to establish a strategic partnership in vaccine development and manufacturing.
  • Collaboration agreement with Vaxxas to develop a second-generation typhoid conjugate vaccine
  • Strategic Equity investment in Novavax
  • Donation to Local Community in Yecheon and Mungyeong,
  • Published 2023 ESG Report
  • Signed MOU with the Government Pharmaceutical Organization (GPO)
  • Announced positive results from its Phase II clinical trials in infants of its 21-valent pneumococcal conjugate vaccine candidate, ‘GBP410’ (Sanofi)
  • Signed a research collaboration agreement on influenza research with the Doherty Institute
  • Granted Emergency Use Listing by the World Health Organization (SKYCovione™)
  • Achieved Marketing Auhorization from UK MHRA (SKYCovione™)
  • Signed CMO agreement with MSD for Next-Generation Zaire Ebola Vaccine Candidate
  • Achieved ISO 27001 Certification
  • Received approval of world-first cell culture based quadrivalent influenza vaccine in Chile
  • Received biologics license application approval of shingles vaccine in Malaysia
  • 2022
  • Published first TCFD report
  • Received 'Grade A' rating on ESG Evaluation from the Korea Institute of Corporate Governance & Sustainability
  • Donated to international Vaccine Institute to support global vaccine R&D
  • Signed a MOU to co-develop new vaccine platforms (Hilleman Laboratories)
  • Signed agreement to develop mRNA Vaccines (CEPI)
  • Achieved adolescent authorization of 'Nuvaxovid' by KMFDS (Novavax, KMFDS)
  • Submitted CMA to the EMA (SKYCovion™)
  • Submitted CMA to the MHRA (SKYCovion™)
  • Agreement to Manufacture COVID-19 Vaccine Containing Omicron Variant (Novavax)
  • Achieved BLA of SKYCovione™ (KMFDS)
  • Held SK bioscience Global Forum
  • Published first ESG report
  • Achieved BLA of SKYTyphoid™ for export
  • Achieved Turkish GMP Certification (TITCK)
  • Agreed SKY Varicella® distribution(PAHO)
  • Signed Advance Purchase Agreement of GBP510(KDCA)
  • Obtained additional EU-GMP Certification for COVID-19 Vaccine Facilities
  • Authorized ‘Nuvaxovid’ by KMFDS (Novavax, KMFDS)
SK L HOUSE(안동 백신공장) 사진
  • 2021
  • Earned the highest sales and operating profit
  • Funded to develop a vaccine candidate against sarbecovirus (CEPI)
  • Established ‘Park Mahnhoon Award’ (IVI)
  • Submitted BLA submission for approval of the COVID-19 vaccine candidate, ‘NVX-CoV2373’ (Novavax, KMFDS)
  • Signed an agreement to extend capacity reservations for manufacturing COVID-19 vaccines (CEPI)
  • Phase III trial for COVID-19 vaccine candidate 'GBP510'
  • MOU for expansion of factories and site (North Gyeongsang Province, Andong city)
  • Secured funding for Phase III clinical trial of COVID-19 vaccine candidate 'GBP510' (CEPI)
  • Obtained EU-GMP Certification for COVID-19 Vaccine Facilities
  • New listed on KOSPI(Korea Composite Stock Price Index)
  • Funded to develop a vaccine candidate against COVID-19 (SARS-CoV-2) variants (CEPI)
  • Signed licensing & purchase agreement for Novavax’s COVID-19 vaccine candidate (Novavax, KDCA)
  • Initiated clinical trials of 'GBP510'
  • Submitted application for export of typhoid vaccine (IVI, Bill & Melinda Gates Foundation)
  • 2020
  • Initiated clinical trial for COVID-19 vaccine (GBP510, NBP2001)
  • Announced as WAVE2 by CEPI with GBP510 (COVID-19 vaccine)
  • Exported SKYVaricella® Inj. to Turkey
  • Signed CDMO agreement with Novavax for COVID-19 vaccine
  • Signed CMO agreement with AstraZeneca for the consigned production of COVID-19 vaccine
  • Signed capacity reservation with CEPI for COVID-19 vaccine
  • Secured funding for development of COVID-19 from the Bill & Melinda Gates Foundation
  • Selected COVID-19 vaccine candidate for national project
  • Began independent development of COVID-19 vaccine
  • Initiated Phase II clinical trial for the next-generation pneumococcal conjugate vaccine co-developed with Sanofi Pasteur
SK L HOUSE image
  • 2019
  • Gained WHO PQ for SKYCellflu® prefilled syringe/SKYCellflu®Quadrivalent prefilled syringe (world’s first for cell-cultured influenza vaccine)
  • Obtained WHO PQ for SKYVaricella® as world’s second
  • Intiated export influenza vaccine, SKYCellflu®, to Asian countries
  • 2018
  • MOU with North Gyeonggi province and Andong city for expansion of L HOUSE (Vaccine Plant)
  • SK bioscience launched (Spun off from the vaccine business sector of SK chemical)
  • Signed agreement with Sanofi Pasteur to license out cell-culture technology for producing cell culture-based influenza vaccines
  • Launched SKY Varicella®
2015 - 2017
The pinnacle of in-house technology
  • 2017
  • Launched SKYZoster® Inj., world’s second shingles vaccine
  • Supply of SKYCellflu®Quadrivalent to Myanmar
  • Signed an agreement with international organization PATH to develop and produce pediatric enteritis vaccine for developing countries
  • 2016
  • Selected health and safety management indicators (L House [Vaccine Plant]); received OHSAS18001, KOSHA18001 certification
  • Launched SKYCellflu® Quadrivalent, world’s first quadrivalent cell culture-based influenza vaccine
  • Obtained approval for SKYPneumo®, the first domestically produced PCV13 vaccine
  • 2015
  • Launched SKYCellflu®, Korea’s first trivalent cell culture-based influenza vaccine
Sky Zoster Inj image
2012 - 2014
Growth takes a leap forward
  • 2014
  • Established strategic partnership with Sanofi Pasteur for co-development of next-generation pneumococcal conjugate vaccine
  • Received KGMP certification for L HOUSE
  • 2013
  • Received LEED GOLD certification for L HOUSE
  • Established partnership with IVI (International Vaccine Institute) to collaborate on the development of a new typhoid conjugate vaccine
  • 2012
  • Established L HOUSE
Image of strategic partnership established with Sanofi Pasteur
2001 - 2009
Into the domestic healthcare market
  • 2005
  • Established vaccine R&D Center
  • 2001
  • Acquired Dongshin Pharm (vaccines, blood products)
Electron micrograph image